title: Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants.
abstract: To improve efficacy of DNA vaccination, various approaches have been developed, including the use of plasmid expressing co-stimulatory molecules as molecular adjuvants. In this study, we investigated whether co-inoculation of a construct expressing either 4-1BBL or OX40L as the molecular adjuvant with FMDV DNA vaccine, pcD-VP1, can increase immune responses and protective efficacies. Compared to the group immunized with pcD-VP1 alone, the co-inoculation of either molecular adjuvant induced a higher ratio of IgG2a/IgG1, higher levels of expression of IFN-gamma in CD4(+) and CD8(+) T cells and antigen-specific CTL responses, and more importantly provided an enhanced protection against the live FMDV challenge in animals. Concurrently, 4-1BBL as the molecular adjuvant dramatically reduced the viral loads of FMDV in vivo after the challenge. Together, the results demonstrate that co-stimulatory molecules 4-1BBL and OX40L can enhance the antigen-specific cell-mediated responses elicited by VP1 DNA vaccine and provide an enhanced protective efficacy with the reduced viral loads.
authors.affiliation: State Key Laboratory for Agro-Biotechnology and the Key Laboratory of Agro-Microbial Resources and Applications of MOA, China Agricultural University, Beijing 100094, China.
authors.forename: Chong
authors.initials: C
authors.lastname: Xiao
authors.forename: Huali
authors.initials: H
authors.lastname: Jin
authors.forename: Yanxin
authors.initials: Y
authors.lastname: Hu
authors.forename: Youmin
authors.initials: Y
authors.lastname: Kang
authors.forename: Junpeng
authors.initials: J
authors.lastname: Wang
authors.forename: Xiaogang
authors.initials: X
authors.lastname: Du
authors.forename: Yu
authors.initials: Y
authors.lastname: Yang
authors.forename: Ruiping
authors.initials: R
authors.lastname: She
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
mesh_terms: D053330:4-1BB Ligand / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics; D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D005536:Foot-and-Mouth Disease / Q000097:blood / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D029544:Foot-and-Mouth Disease Virus / Q000276:immunology*; D006168:Guinea Pigs; D006367:HeLa Cells; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007273:Injections, Intramuscular; D007371:Interferon-gamma / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D053278:OX40 Ligand / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage; D019562:Viral Load; D014765:Viral Vaccines / Q000008:administration & dosage*
chemical_list: D053330:4-1BB Ligand; D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007074:Immunoglobulin G; D053278:OX40 Ligand; D019444:Vaccines, DNA; D014765:Viral Vaccines; D007371:Interferon-gamma